Elon Musk’s Neuralink startup has raised an additional $43 million in venture capital. This is stated in a report to the U.S. Securities and Exchange Commission (SEC), according to TechCrunch.
According to the document, the previous tranche from Peter Thiel’s Founders Fund increased from $280 million to $323 million in early August. A total of 32 investors participated in the financing.
Recently, Neuralink has not disclosed its valuation. However, in June, Reuters reported that the company was valued at about $5 billion after private stock deals.
Earlier it became known that the startup received approval from an independent supervisory committee to start recruiting participants for the first trial of a brain implant for patients with paralysis.
People with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis are eligible to participate in the study. The trial itself will last about six years.
In the spring, the company announced that it had received approval for the first human clinical trial of brain implants from the U.S. Food and Drug Administration (FDA).